group IVF sPLA2 Double Nickase Plasmid (h): sc-415215-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- group IVF sPLA2 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- group IVF sPLA2 Double Nickase Plasmid (h) and group IVF sPLA2 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting PLA2G4F. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: group IVF sPLA2 Antibody (C-6): sc-398729
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
group IVF sPLA2 Double Nickase Plasmid (h) | sc-415215-NIC | 20 µg | $410.00 |
PLA2G4F encodes group IVF secretory phospholipase A2 (sPLA2), an extracellular lipolytic enzyme that hydrolyzes membrane glycerophospholipids to release free fatty acids and lysophospholipids. Through regulation of arachidonic acid availability, PLA2G4F can influence eicosanoid biosynthesis and lipid mediator signaling that intersects with inflammatory responses, epithelial barrier biology, and stress-adaptive membrane remodeling. Altered phospholipid turnover and sPLA2 activity have been examined in contexts of chronic inflammation and cancer-associated lipid reprogramming, where shifts in lipid mediators and membrane composition can affect proliferation, migration, and immune crosstalk.
group IVF sPLA2 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the PLA2G4F locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within PLA2G4F. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt PLA2G4F function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of PLA2G4F-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.